Bryn Pharma Strengthens Board of Directors with Appointments of Commercial Veterans Sandy Loreaux and William D. Humphries

RALEIGH, N.C.--(BUSINESS WIRE)-- Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced the appointments of Sandy Loreaux and William D. Humphries to its Board of Directors. Ms. Loreaux and Mr. Humphries join Anne Whitaker and Lisa Licht to round out the senior directors focused on commercialization of UTULY™.

“Sandy and Bill bring decades of experience and strong commercialization skill sets to our Board,” said Steven Hartman, Chairman of the Board of Directors. “With the completion of the UTULY™ clinical program, we look forward to working with Sandy and Bill to plan for the U.S. market launch.”

Ms. Loreaux has over 25 years of experience in the pharmaceutical industry. She currently leads Covis Pharma’s U.S. Operations in her role as U.S. President. Sandy joined Covis in November 2021 after previously serving as Senior Vice President and General Manager, U.S. Critical Care for Mallinckrodt Pharmaceuticals. She has led multiple market access initiatives in her roles as SVP, Head of Market Access at Mallinckrodt Pharmaceuticals and SVP, Head of Market Access, and Commercial Operations at Bausch Health. Ms. Loreaux spent the first 19 years of her career at Sanofi and its legacy companies in various roles of increasing responsibility across medical affairs, sales, marketing and market access. Ms. Loreaux is a pharmacist by training and has a degree from Temple University School of Pharmacy in Philadelphia. As a mother of children who were diagnosed with life-threatening food allergies as infants, Ms. Loreaux brings a personal passion and commitment to bringing epinephrine delivery alternatives to market.

Mr. Humphries has more than 30 years of experience building and leading commercial-stage pharmaceutical organizations. He is currently the Chief Executive Officer of Isosceles Pharmaceuticals, a position he has held since May 2021. Previously, Mr. Humphries served as President of Ortho Dermatologics, a Bausch Health Company. Before joining Ortho Dermatologics, he served as President and Chief Executive Officer of the North American business of Merz, an affiliate of Merz Pharma Group, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics Inc., and Merz Pharma Canada Ltd. Before joining Merz, he served in several leadership positions with Stiefel Laboratories, including Chief Commercial Officer and President, where he spearheaded two significant acquisitions and led the global integration of Stiefel into GlaxoSmithKline. Earlier in his career, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, concluding as Vice President of its U.S. skincare business.

“Sandy and Bill’s appointments bring deep commercial expertise to Bryn that will help us navigate the transition from an R&D organization to a fully integrated commercial organization,” said David Dworaczyk, Ph.D., CEO of Bryn Pharma. “They are joining Bryn’s board at a critical time and we are thrilled to welcome them to our team.”

About Bryn Pharma

Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005178/en/